Comment on: Boden et al. (2007) Combined Use of Rosiglitazone and Fenofibrate in Patients with Type 2 Diabetes: Prevention of Fluid Retention: Diabetes 56:248–255
- From the Unit for Metabolic Medicine, Department of Diabetes and Endocrinology, Cardiovascular Division, King's College London School of Medicine, Guy's Hospital, King's College London, London, U.K
- Address correspondence to Dr. J. Karalliedde, Unit for Metabolic Medicine, 5th Floor Thomas Guy House, Guy's Hospital, St. Thomas Street, London SE1 9RT. E-mail: j.karalliedde{at}kcl.ac.uk
The finding and conclusions of the recent article published by Boden et al. (1) need to be interpreted with caution in view of several factors.
The authors state that the combination of rosiglitazone (RGZ) and fenofibrate (FFB) “completely prevented the water retention and weight gain associated with RGZ.” FFB has significant peroxisome proliferator–activated receptor (PPAR)-α activity (2,3) and is widely used for the treatment of …
